Chronic wounds in high-risk patients simply demand more. GRAFIX PL PRIME◊ Membrane brings the full biologic profile of placental tissue into a lyopreserved, clinic-ready format. This BioTissue is built for patients who can’t afford another failed closure.
At a glance
- Lyopreserved placental membrane containing native ECM, growth factors, and viable cells.1,2
- Designed for difficult-to-heal diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and complex surgical sites.
- Room-temperature storage and multiple graft sizes (2–12 cm²) for precise coverage and minimal waste.
Evidence that raises the bar
Within the GRAFIX Membrane portfolio, randomized and real-world data have demonstrated meaningful advantages versus standard care and other cellular/tissue-based products in chronic wounds.
Key findings include:3
- 3x more DFUs closed with GRAFIX Membrane plus standard care vs standard care alone (62.0% vs 21.3%; p=0.0001) in a multicenter RCT.
- Closure 27.5 days sooner vs standard care alone.
National Institute for Health and Care Excellence (NICE) rated the trial as the highest overall effect among dermal substitute studies in DFUs, with high-quality evidence and no serious risk of bias.4
GRAFIX PL PRIME offers biologic advantages in a lyopreserved format designed for everyday access in the clinic.
Built for your complex wound population
Use GRAFIX PL PRIME when you need a biologic that can keep pace with your most challenging patients:
- Neuropathic and ischemic DFUs
- VLUs
- Chronic surgical and post-operative wounds
Primarily sized for moderate-area wounds, GRAFIX PL PRIME fits the “sweet spot” of complex ulcers seen in high-volume wound clinics.
- . Dhall S, et al. Plos One. 2018; 13 (10): e0204060.
- Mamede AC, Carvalho, MJ, Abrantes AM, et al. Amniotic membrane: from structure and functions to clinical applications. Cell Tissue Res. 2012; 349 (2): 447-458.
- Lavery LA, Fulmer J, Shebetka KA, et al. The efficacy and safety of GRAFIX◊ for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J. 2014;11(5):554–560.
- Diabetic foot problems: prevention and management. National Institute for Health and Care Excellence (NICE) guideline. Published: January 2016. https://www.nice.org.uk/guidance/ng19/evidence/appendix-i-grade-profiles-15672915540.